New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Investigative Medicine

• Publication date

  2016-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/jim-2016-000151PMID 27252470
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Do traditional anti-seizure drugs have a future? A review of potential anti-seizure drugs in clinical development.

  2016cited by this paper
• Challenges in the clinical development of new antiepileptic drugs.

  2016cited by this paper
• The direct cost of epilepsy in the United States: A systematic review of estimates

  2015cited by this paper
• Antiepileptic drugs--a review.

  2015cited by this paper
• Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.

  2015cited by this paper
• Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials.

  2015cited by this paper
• Effectiveness and Tolerability of Perampanel in Children and Adolescents with Refractory Epilepsies: First Experiences

  2015cited by this paper
• Perampanel efficacy and safety by gender: Subanalysis of phase III randomized clinical studies in subjects with partial seizures

  2015cited by this paper
• Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy

  2015cited by this paper
• Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update

  2015cited by this paper
• Clobazam is equally safe and efficacious for seizures associated with Lennox-Gastaut syndrome across different age groups: Post hoc analyses of short- and long-term clinical trial results.

  2015cited by this paper
• Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit.

  2015cited by this paper
• Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.

  2015cited by this paper
• Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.

  2015cited by this paper
• Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.

  2015cited by this paper
• Clobazam: An effective add‐on therapy in refractory status epilepticus

  2015cited by this paper
• Perampanel in the treatment of partial seizures: Time to onset and duration of most common adverse events from pooled Phase III and extension studies.

  2015cited by this paper
• Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability

  2015cited by this paper
• Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.

  2015cited by this paper
• The interaction potential of retigabine (ezogabine) with other antiepileptic drugs.

  2014cited by this paper
• Perampanel for adjunctive treatment of partial‐onset seizures: A pooled dose–response analysis of phase III studies

  2014cited by this paper
• Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307

  2014cited by this paper
• Effect of hemodialysis on pharmacokinetics of ezogabine/retigabine and its N-acetyl metabolite in patients with end stage renal disease.

  2014cited by this paper
• Caregiver Burden in Epilepsy: Determinants and Impact

  2014cited by this paper
• Clobazam monotherapy for partial-onset or generalized-onset seizures.

  2014cited by this paper
• Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy

  2014cited by this paper
• Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years

  2014cited by this paper
• Long term retention of retigabine in a cohort of people with drug resistant epilepsy.

  2014cited by this paper
• Withdrawal-related adverse events from clinical trials of clobazam in Lennox-Gastaut syndrome.

  2014cited by this paper
• Old versus New: Why Do We Need New Antiepileptic Drugs?

  2014cited by this paper
• Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability.

  2014cited by this paper
• Possible effect of perampanel on focal status epilepticus after generalized tonic–clonic status epilepticus

  2014cited by this paper
• Clobazam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience.

  2014cited by this paper
• Clinical pharmacokinetics of retigabine/ezogabine.

  2013cited by this paper
• Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures.

  2013cited by this paper
• The adverse event profile of perampanel: meta‐analysis of randomized controlled trials

  2013cited by this paper
• The effects of ethanol on the pharmacokinetics, pharmacodynamics, safety, and tolerability of ezogabine (retigabine).

  2013cited by this paper
• Research advances in basic mechanisms of seizures and antiepileptic drug action

  2013cited by this paper
• Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies

  2013cited by this paper
• Safety and tolerability of perampanel: a review of clinical trial data

  2013cited by this paper
• Ezogabine: A Novel Antiepileptic for Adjunctive Treatment of Partial‐Onset Seizures

  2013cited by this paper
• Molecular Expression and Pharmacological Evidence for a Functional Role of Kv7 Channel Subtypes in Guinea Pig Urinary Bladder Smooth Muscle

  2013cited by this paper
• Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome.

  2013cited by this paper
• AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel

  2013cited by this paper
• Antiepileptic drugs and suicidality: An expert consensus statement from the Task Force on Therapeutic Strategies of the ILAE Commission on Neuropsychobiology

  2013cited by this paper
• Clobazam

  2013cited by this paper
• Retigabine as add‐on treatment of refractory epilepsy – a cost‐utility study in a Swedish setting

  2013cited by this paper
• Evaluation of adjunctive perampanel in patients with refractory partial‐onset seizures: Results of randomized global phase III study 305

  2013cited by this paper
• Indirect comparison of clobazam and other therapies for Lennox–Gastaut syndrome

  2013cited by this paper
• Perampanel, a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial‐onset seizures: Interim results from phase III, extension study 307

  2013cited by this paper
• Profile of perampanel and its potential in the treatment of partial onset seizures

  2013cited by this paper
• New drug classes for the treatment of partial onset epilepsy: focus on perampanel

  2013cited by this paper
• Introduction to Institute of Medicine Report

  2012cited by this paper
• Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate

  2012cited by this paper
• A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus.

  2012cited by this paper
• Tolerability and safety of perampanel: two randomized dose‐escalation studies

  2012cited by this paper
• Neurological and Psychiatric Sequelae of Developmental Exposure to Antiepileptic Drugs

  2012cited by this paper
• Adjunctive perampanel for refractory partial-onset seizures

  2012cited by this paper
• Perampanel: Getting AMPed for AMPA Targets

  2012cited by this paper
• Epilepsy: Perampanel—new promise for refractory epilepsy?

  2012cited by this paper
• Differential effects of antiepileptic drugs on neonatal outcomes.

  2012cited by this paper
• The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first‐in‐class antiepileptic drug that targets KCNQ (Kv7) potassium channels

  2012cited by this paper
• Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials.

  2012cited by this paper
• Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study.

  2012cited by this paper
• GABAA Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine Clobazam

  2012cited by this paper
• Randomized phase III study 306

  2012cited by this paper
• Perampanel Study 207: long‐term open‐label evaluation in patients with epilepsy

  2012cited by this paper
• Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy

  2011cited by this paper
• Perampanel: A novel, orally active, noncompetitive AMPA‐receptor antagonist that reduces seizure activity in rodent models of epilepsy

  2011cited by this paper
• Clobazam as an adjunctive therapy in treating seizures associated with Lennox–Gastaut syndrome

  2011cited by this paper
• Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome

  2011cited by this paper
• Revisiting AMPA Receptors as an Antiepileptic Drug Target

  2011cited by this paper
• Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy

  2010cited by this paper
• Clobazam in refractory childhood epilepsy

  2010cited by this paper
• Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX).

  2009cited by this paper
• Clobazam in the treatment of Lennox‐Gastaut syndrome

  2009cited by this paper
• Quantifying the response to antiepileptic drugs

  2008cited by this paper
• Benzodiazepines in epilepsy: pharmacology and pharmacokinetics

  2008cited by this paper
• Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.

  2008cited by this paper
• Idiosyncratic Adverse Reactions to Antiepileptic Drugs

  2007cited by this paper
• Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures

  2007cited by this paper
• RETIGABINE :B ENDING POTASSIUM CHANNELS TO OUR WILL The New Anticonvulsant Retigabine Favors Voltage-dependent Opening of the Kv7.2 (KCNQ2) Channel by Binding to Its Activation Gate

  2005cited by this paper
• Clobazam as a New Antiepileptic Drug and Clorazepate Dipotassium as an Alternative Antiepileptic Drug in Japan

  2004cited by this paper
• In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19.

  2004cited by this paper
• Pregabalin Add‐on Treatment: A Randomized, Double‐blind, Placebo‐controlled, Dose–Response Study in Adults with Partial Seizures

  2004cited by this paper
• Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects

  2003cited by this paper
• Use of clobazam for the treatment of refractory complex partial seizures.

  2003cited by this paper
• Effects of age and sex on the disposition of retigabine

  2003cited by this paper
• Challenges in the Clinical Development of New Antiepileptic Drugs

  2002cited by this paper
• Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission.

  2002cited by this paper
• Multiple‐Dose, Linear, Dose‐Proportional Pharmacokinetics of Retigabine in Healthy Volunteers

  2002cited by this paper
• Anticonvulsants and breast feeding: a critical review.

  2000cited by this paper
• Early identification of refractory epilepsy.

  2000cited by this paper
• The ILAE/IBE/WHO Global Campaign against Epilepsy: Bringing Epilepsy "Out of the Shadows"

  2000cited by this paper
• Clobazam for the treatment of intractable childhood epilepsy.

  2000cited by this paper
• Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV).

  1999cited by this paper
• Metabolism of retigabine (D-23129), a novel anticonvulsant.

  1999cited by this paper
• Clobazam Has Equivalent Efficacy to Carbamazepine and Phenytoin as Monotherapy for Childhood Epilepsy

  1998cited by this paper
• Clobazam in partial status epilepticus.

  1998cited by this paper
• Seizures and epilepsy in the elderly.

  1997cited by this paper

• Palladium‐Catalyzed Site‐Selective C─H Alkoxylation Using Biorelevant Heterocyclic Directing Groups

  2025cites this paper
• Biorelevant Weakly Coordinating Directing Group Assisted C-H Alkenylation with Cyclopropanols via Sequential C-H/C-C Activation.

  2023cites this paper
• Racial and Ethnic Differences in Antiseizure Medications Among People With Epilepsy on Medicaid

  2023cites this paper
• Ru-Catalyzed C-H alkenylation on the arene ring of pirfenidone using pyridone as a directing group.

  2022cites this paper
• Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy

  2022cites this paper
• Antiepileptic drugs

  2021cites this paper
• Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy

  2020cites this paper
• Molecular basis and restoration of function deficiencies of Kv7.4 variants associated with inherited hearing loss.

  2020cites this paper
• Targeting Ionotropic Glutamate Receptors In The Treatment Of Epilepsy.

  2020cites this paper
• Improving clinical trial outcomes in amyotrophic lateral sclerosis

  2020cites this paper
• Liquid chromatographic methods for determination of the new antiepileptic drugs stiripentol, retigabine, rufinamide and perampanel: A comprehensive and critical review

  2020cites this paper
• Antiepileptic drugs

  2020cites this paper
• Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures

  2019cites this paper
• How safe is bone health in patients on newer or enzyme inhibitor antiepileptic drugs?

  2019cites this paper
• Timing use of novel anti-epileptic drugs: is earlier better?

  2019cites this paper
• Pharmacokinetic considerations for anti-epileptic drugs in children

  2019cites this paper
• Real-Life Effectiveness and Tolerability of Perampanel in Pediatric Patients Aged 4 Years or Older with Epilepsy: A Korean National Multicenter Study

  2019cites this paper
• Efficacy and tolerability of adjunctive perampanel treatment in children under 12 years of age with refractory epilepsy

  2018cites this paper
• Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel

  2018cites this paper
• Drugs in clinical development for the treatment of amyotrophic lateral sclerosis

  2017cites this paper